Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy
Rash and hypersensitivity-related adverse events and AKI were more frequently reported with the ABCP and A + CbP regimens, respectively. These observations may help generate hypotheses regarding regimen-specific adverse event profiles and support future studies toward individualized chemotherapy.
Authors
- Toru Imai (ORCID: https://orcid.org/0000-0002-8648-7571)
- K. Hanada (ORCID: https://orcid.org/0000-0002-9041-5589)
- Katsuyuki Hazama
- Shinsaku Washinosu
- Naohiro Tochikura (ORCID: https://orcid.org/0000-0002-8782-1674)
- Susumu Ootsuka
Institutions
- Meiji Pharmaceutical University (JP)
- Nihon University Itabashi Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1186/s40780-025-00522-6
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05